Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to analyze and interpret the results from an open-label trial in unilateral knee osteoarthritis patients.
[en] BACKGROUND: The aim of this study was to investigate the effects of chondroitin sulfate (CS) on the serum levels of Coll2-1 in patients with knee OA. METHODS: Seventy two patients with unilateral symptomatic knee OA were involved in a post-authorization open-label study evaluating CS (800 mg/day). The primary outcome was the % relative change in serum Coll2-1 (sColl2-1). The secondary outcomes were the evaluation of pain (VAS) and function (Lequesne's Index). Responders and non-responders were classified according to OMERACT-OARSI recommendations. Finally, an original cut-off method was applied to categorize patients and interpret individual variations in serum levels of Coll2-1. RESULTS: Patients showed no difference in the sColl2-1 levels at baseline. When considering responders and non-responders from the ITT population, a significant difference was found for Coll2-1 at 3 months (p = 0.030) and 6 months (p = 0.038). A decrease in pain (VAS) and an improvement in function (LI) were recorded throughout the visits (p < 0.01). Considering an intra-batch cut-off of 21 %, CS decreased Coll2-1 serum levels between baseline and 1-month visit compared to the value of Coll2-1 before treatment (screening visit) which can be interpreted as a drastic reduction of the proportion of patients with an increase of Coll2-1 over 21 % (reduction from 13 to 3 %). It also consisted in a more important proportion of patients with a decrease in Coll2-1 (from 5 to 10 %). CONCLUSION: This study proposes a new approach for the analysis and the interpretation of the individual variation in biomarker levels and introduces the notion of metabolic responders. TRIAL REGISTRATION: ID ISRCTN63795830 . The trial was retrospectively registered on 2 October, 2015.
Disciplines :
Rheumatology
Author, co-author :
Moller, Ingrid
Gharbi, Myriam
Martinez Serrano, Helena
Herrero Barbero, Marta
Verges Milano, Josep
Henrotin, Yves ; Université de Liège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Language :
English
Title :
Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to analyze and interpret the results from an open-label trial in unilateral knee osteoarthritis patients.
Goldring, S.R., Goldring, M.B., Clinical aspects, pathology and pathophysiology of osteoarthritis (2006) J Musculoskelet Neuronal Interact, 6 (4), pp. 376-378. , 1:STN:280:DC%2BD28jkslWrug%3D%3D 17185832
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework (2001) Clin Pharmacol Ther, 69 (3), pp. 89-95. , Biomarkers Definitions Working G
Kraus, V.B., Burnett, B., Coindreau, J., Cottrell, S., Eyre, D., Gendreau, M., Gardiner, J., Henrotin, Y., Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis (2011) Osteoarthritis Cartilage, 19 (5), pp. 515-542. , 1:STN:280:DC%2BC3MrgvFGquw%3D%3D 21396468 3568396
Lotz, M., Martel-Pelletier, J., Christiansen, C., Brandi, M.L., Bruyere, O., Chapurlat, R., Collette, J., Kanis, J.A., Value of biomarkers in osteoarthritis: current status and perspectives (2013) Ann Rheum Dis, 72 (11), pp. 1756-1763. , 1:CAS:528:DC%2BC3sXhslymsb%2FN 23897772 3812859
Henrotin, Y., Addison, S., Kraus, V., Deberg, M., Type II collagen markers in osteoarthritis: what do they indicate? (2007) Curr Opin Rheumatol, 19 (5), pp. 444-450. , 1:CAS:528:DC%2BD2sXpvVensbg%3D 17762609
Birmingham, J.D., Vilim, V., Kraus, V.B., Collagen biomarkers for arthritis applications (2007) Biomark Insights, 1, pp. 61-76. , 19690637 2716783
Henrotin, Y., Deberg, M., Dubuc, J.E., Quettier, E., Christgau, S., Reginster, J.Y., Type II collagen peptides for measuring cartilage degradation (2004) Biorheology, 41 (3-4), pp. 543-547. , 1:CAS:528:DC%2BD2cXlvF2hsLc%3D 15299285
Deberg, M., Labasse, A., Christgau, S., Cloos, P., Bang Henriksen, D., Chapelle, J.P., Zegels, B., Henrotin, Y., New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis (2005) Osteoarthritis Cartilage, 13 (3), pp. 258-265. , 15727893
Deberg, M.A., Labasse, A.H., Collette, J., Seidel, L., Reginster, J.Y., Henrotin, Y.E., One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression (2005) Osteoarthritis Cartilage, 13 (12), pp. 1059-1065. , 1:STN:280:DC%2BD2MnjtVOrsw%3D%3D 16154771
Dougados, M., Symptomatic slow-acting drugs for osteoarthritis: what are the facts? (2006) Joint Bone Spine, 73 (6), pp. 606-609. , 1:CAS:528:DC%2BD2sXhsFahu74%3D 17126058
Clegg, D.O., Reda, D.J., Harris, C.L., Klein, M.A., O'Dell, J.R., Hooper, M.M., Bradley, J.D., Jackson, C.G., Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis (2006) N Engl J Med, 354 (8), pp. 795-808. , 1:CAS:528:DC%2BD28XhslyqsrY%3D 16495392
Uebelhart, D., Malaise, M., Marcolongo, R., DeVathaire, F., Piperno, M., Mailleux, E., Fioravanti, A., Vignon, E., Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo (2004) Osteoarthritis Cartilage, 12 (4), pp. 269-276. , 15023378
Uebelhart, D., Thonar, E.J., Delmas, P.D., Chantraine, A., Vignon, E., Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study (1998) Osteoarthritis Cartilage, 6 (Suppl A), pp. 39-46. , 9743819
Kahan, A., Uebelhart, D., De Vathaire, F., Delmas, P.D., Reginster, J.Y., Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial (2009) Arthritis Rheum, 60 (2), pp. 524-533. , 1:CAS:528:DC%2BD1MXjt1Cnsr4%3D 19180484
Verbruggen, G., Goemaere, S., Veys, E.M., Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA (1998) Osteoarthritis Cartilage, 6 (Suppl A), pp. 37-38. , 9743818
Verbruggen, G., Goemaere, S., Veys, E.M., Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs (2002) Clin Rheumatol, 21 (3), pp. 231-243. , 1:STN:280:DC%2BD38zms1eisQ%3D%3D 12111630
Wildi, L.M., Raynauld, J.P., Martel-Pelletier, J., Beaulieu, A., Bessette, L., Morin, F., Abram, F., Pelletier, J.P., Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI (2011) Ann Rheum Dis, 70 (6), pp. 982-989. , 21367761 3086081
Altman, R.D., Asch, E., Bloch, D.A., Bole, G., Borenstein, D., Brandt, K.D., Christy, W., Hochberg, M., Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee (1986) Arthritis Rheum, 29, pp. 1039-1049. , 1:STN:280:DyaL283psF2msQ%3D%3D 3741515
Kellgren, J.H., Lawrence, J.S., Radiological assessment of osteo-arthrosis (1957) Ann Rheum Dis, 16 (4), pp. 494-502. , 1:STN:280:DyaG1c%2FktFeltQ%3D%3D 13498604 1006995
Wolfe, F., Smythe, H.A., Yunus, M.B., Bennett, R.M., Bombardier, C., Goldenberg, D.L., Tugwell, P., Clark, P., The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee (1990) Arthritis Rheum, 33 (2), pp. 160-172. , 1:STN:280:DyaK3c7ms1Sguw%3D%3D 2306288
Wolfe, F., Clauw, D.J., Fitzcharles, M.A., Goldenberg, D.L., Hauser, W., Katz, R.S., Mease, P., Winfield, J.B., Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia (2011) J Rheumatol, 38 (6), pp. 1113-1122. , 21285161
Pham, T., Van Der Heijde, D., Lassere, M., Altman, R.D., Anderson, J.J., Bellamy, N., Hochberg, M., Woodworth, T., Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria (2003) J Rheumatol, 30 (7), pp. 1648-1654. , 12858473
Huskisson, E.C., Measurement of pain (1982) J Rheumatol, 9 (5), pp. 768-769. , 1:STN:280:DyaL3s%2FosFGqsg%3D%3D 6184474
Lequesne, M.G., The algofunctional indices for hip and knee osteoarthritis (1997) J Rheumatol, 24 (4), pp. 779-781. , 1:STN:280:DyaK2s3ls1WrtA%3D%3D 9101517
Kraus, V.B., Patient evaluation and OA study design: OARSI/biomarker qualification (2012) HSS J, 8 (1), pp. 64-65. , 23372536
Gabay, C., Medinger-Sadowski, C., Gascon, D., Kolo, F., Finckh, A., Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center (2011) Arthritis Rheum, 63 (11), pp. 3383-3391. , 1:CAS:528:DC%2BC3MXhtlOksLnJ 21898340
Lequesne, M., Symptomatic slow-action anti-arthritic agents: a new therapeutic concept? (1994) Rev Rhum Ed Fr, 61 (2), pp. 75-79. , 1:STN:280:DyaK2M%2FgsVehtA%3D%3D 7920505
Wagner, J.A., Williams, S.A., Webster, C.J., Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs (2007) Clin Pharmacol Ther, 81 (1), pp. 104-107. , 1:CAS:528:DC%2BD2sXht1aqtr8%3D 17186007
Conrozier, T., Balblanc, J.C., Richette, P., Mulleman, D., Maillet, B., Henrotin, Y., Rannou, F., Mathieu, P., Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open-label observational prospective study (2012) J Orthop Res, 30 (5), pp. 679-685. , 1:CAS:528:DC%2BC38XjsVWitro%3D 22025307
Henrotin, Y., Chevalier, X., Deberg, M., Balblanc, J.C., Richette, P., Mulleman, D., Maillet, B., Mathieu, P., Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO(2)) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study (2013) J Orthop Res, 31 (6), pp. 901-907. , 1:CAS:528:DC%2BC3sXlvFyisL8%3D 23423846
